Indiana University

Study Participation

     We are always looking for interested volunteers for our research studies.  The amazing breakthroughs in scientific research are due to the wonderful families and individuals who take part in these studies. We could not do this without YOU!

     If you are interested, please take a look at the table below for the current studies that are ongoing on the Indiana University School of Medicine Campus in Indianapolis.  You may also check out a free, national recruitment registry called ResearchMatch funded in part by the National Institutes of Health (NIH) that matches volunteers and researchers working in any number of diseases/studies. For Alzheimer disease and dementia research studies specifically, check out the Alzheimer's Prevention Registry and the Alzheimer's Association's TrialMatch for additional participation opportunties. Also, download this pdf participating-in-alzheimers-research.pdf for general information on Alzheimer disease clinical trials.

Who is needed?

For which study?

Length of study?

Please contact…

Participants need to: 

  • Have a first degree relative with Alzheimer disease caused by a known mutation. 
  • Be at least 18 years of age. 
  • Speak and read English. 
  • Have someone who knows them well and be willing to answer questions about their memory and thinking.
Dominantly Inherited Alzheimer Network (DIAN)

Longitudinally, visiting every 1-3 years, as long as the person is willing. 

Visits include: neurological exam, cognitive evaluation, PET and MRI imaging, informant interview, blood draw and spinal tap.

Compensation: travel, meals, accommodation, and completion of some procedures.


Melissa Wesson



Christina Brown


To participate, volunteers must have a diagnosis of one of the following:

• Probable Alzheimer Disease

• Mild Cognitive Impairment

• Lewy Body Disease

• Frontotemporal Dementia

• Mixed Dementia

• Vascular Dementia

• Parkinson Dementia

This Registry/database is used to capture data for self-referred volunteers and established clinic patients who have interest in participating in clinical research and drug studies now and in the future.

Information regarding research projects will be disclosed prior to enrollment in specific research studies.

Length varies by individual study.

Christina Brown


Families with 3 or more living siblings diagnosed with probable AD.


The Genetics of Late Onset Alzheimer’s Disease (LOAD) Study

Longitudinal; over a lifetime or as long as person is willing.

Visits include: neurological exam, cognitive evaluation, informant interview and provide a blood sample for DNA at first visit.

National Cell Repository for AD


  • People with mild to moderate memory difficulties.
  • 60 years of age or older.
  • Right-handed.
  • Completed at least 8th grade.

Healthy Older Adults Study of Memory.


Study includes brain scans, blood draw, eye exam and cognitive testing.

  • Longitudinal; over a lifetime or as long as person is willing.

  • Assessments are 18 months apart.

  • Each visit is 10.5 hours and will be scheduled over 2 days.

  • Compensation for time and effort provided.

Eileen Tallman


  • Familes with two or more living members with AD or symptoms of serious memory loss.

  • Eager to involve new families from all locations.

The National Cell Repository for Alzheimer's Disease (NCRAD)

  • Longitudinal; over a lifetime or as long as person is willing. 

  • Visits are done by telephone or mail.

National Cell Repository for AD


  • Be 55-90 years of age
  • MMSE score between 20-26.
  • Have Mild Alzheimer Disease.
  • Have amyloid pathology present at screening.
  • Be stable 12 weeks prior to screen if using AChEIs. 

Lilly: H8A-MC-LZAX.

A research study to assess the effects of passive immunization on the progression of mild AD; Solanezumab (LY2062430) versus placebo.

  • Approximately 25 visits within 18 months.

  • Visits are 3-6 hours long.

  • You will receive monthly IV infusion if eligible for study. 


  • $75 for 5 visits
  • $50 for all other visits

Lyla Christner, LPN


  • 65-85years of age.
  • MMSE score of 27-30 if more than high school education
  • MMSE 25-30 if only high school education.


A research study to assess the effects of Solanezumab (LY2062430) versus placebo in slowing cognitive decline in preclinical AD.

  • Approximately 164 weeks.
  • Clinic visit every 4 weeks.


  • $50 for each completed clinic visit.
  • $75 for optional lumbar puncture at visit #5.
  • $125 for final visit of optional lumbar puncture.
  • Complimentary parking.

Nancy McClaskey



Christina Brown



  • Adult, age 60 years and older.
  • Diagnosis of Mild Cognitive Impairment
  • Supported by an adult family member. 
  • Both patient and caregiver would participate and should be able to read and speak English.
Daily Enhancement of Meaningful Activity (DEMA). 
  • 3-month skill-building and health promotion program.

  • 2 face-to-face sessions on IUPUI campus.

  • 4 telephone sessions. 

  • Total time involvement: one hour per week for 3 months

  • Compensation: Up 

    to $60 in gift cards and parking passes as needed.

Christine Richard

Program Manager




  • 66-85 years of age.

  • Up to 90 years of age with medical monitor approval.

  • MMSE 14-26.

  • AChEIs, Namenda if stable 12 weeks prior to screen.



Placebo-controlled study of effects of daily administration of AC-1204 in participants with mild to moderate AD. 

  • 26 weeks with optional 26 week extension.

  • Screening period of up to 28 days to determine eligibility followed by treatment period.


  • 5 clinic visits - $75 each
  • Phone interviews - $25 each.

Scott Herring



Christina Brown


  • 55-85 years of age.
  • MMSE score of 20 or greater.


Study of Nasal Insulin to Fight Forgetfulness

A multi-center, double blind, placebo-controlled phase II/III study to evaluate impact of nasal inhaled insulin in participants with mild and early AD. 

  • Blind study for 12 months.
  • Followed by 6 months open label (all participants receive insulin).


  • $75 for each completed lumbar puncture.
  • Complimentary parking.

Scott Herring, RN


  • 70 years of age or younger.
  • MMSE score of 20 or greater.

Tau RX

 A double-blind, placebo-controlled, randomized, parallel-group, 12 month safety and efficacy trial of Leuco-methylthioninium bis (hydromethanesulfonate) in subjects with behavior variant Frontotemporal Dementia (bvFTD).

  • Approximately 62 weeks.
  • Volunteer and their caregiver will need to complete 10 study visits at the IU Neuroscience Center
  • Average study visit 3 to 6 hours.


  • $100 for 5 certain visits.
  • $50 for each other visit.

Angie Secrest



Christina Brown


Participants need to:

  • Be 50-90 years of age
  • AChEIs and/or memantine allowed if stable dose for at least 12 weeks prior to baseline
  • Have a BMI<35 at screening
  • Have a MMSE 22+
Eisai - A placebo-controlled, double-blind, parallel-group, dose regimen-finding study to evaluate safety, tolerability, and efficacy of BAN2401 in subjects with early AD, defined as mild cognitive impairment due to AD.
  • Up to 41 months
  • Average visit 3-6 hours


  • Varies from $50 to $100 visit; up to $2600 maximum.

Lyla Christner



Christina Brown